Bayer for ProfessionalsYour Resource Portal

Resources

NUBEQA®▼ (darolutamide) Resources

mHSPC checklist for Nubeqa

Download PDF

Nubeqa patient leaflet

Download PDF

A NUBEQA® (DAROLUTAMIDE) CASE STUDY

Download Here

British Journal of Nursing May 2022

Supplement Authored by Mr Andrew Hunnisett and Ms Debbie Victor

Download PDF

nmCRPC checklist for NUBEQA

Download PDF

Highlights from ASCO-GU and EAU

The latest updates in the nmCRPC and mHSPC landscape

Download Here

NUBEQA^▼ Prescribing Information

NUBEQA®▼ (darolutamide) Guidelines in nmCRPC

NUBEQA GB Prescribing Information

NUBEQA NI Prescribing Information

PP-NUB-GB-1306, February 2024

NUBEQA®▼ (darolutamide)

In nmCRPC and mHSPC

NUBEQA GB Prescribing Information

NUBEQA NI Prescribing Information

PP-NUB-GB-1317, February 2024

NUBEQA®▼ (darolutamide) Guidelines in mHSPC

NUBEQA GB Prescribing Information

NUBEQA NI Prescribing Information

PP-NUB-GB-1578, February 2024

PP-NUB-GB-1312 | February 2024

Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.

Further information is available on the "contact" tab at www.bayer.co.uk.